Clinical Trial Update: Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of tolvaptan in autosomal dominant polycystic kidney disease has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Polycystic Kidney Disease, Autosomal Dominant | Phase 3 | Status: COMPLETED | Results posted: 2017-07-02